Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.
Through the deal, Sylvester will have access to Syapse's precision medicine platform for cancer care.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.
The company is seeking partnerships that will enable it to offer its software to more users as part of larger, more integrated systems.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
The companies are combining their respective software platforms to provide an end-to-end genomic testing solution for hospital labs.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.